Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial

BACKGROUND: Although Hizentra is indicated for immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies, phase III trials have focused on patients with primary immunodeficiencies. In this 9-month, real-life, prospective, non-interventional, longitudinal, multicent...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Immunol
Main Authors: Viallard, J. F., Agape, P., Barlogis, V., Cozon, G., Faure, C., Fouyssac, F., Gaud, C., Gourin, M. P., Hamidou, M., Hoarau, C., Husseini, F., Ojeda-Uribe, M., Pavic, M., Pellier, I., Perlat, A., Schleinitz, N., Slama, B.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5041334/
https://ncbi.nlm.nih.gov/pubmed/27687879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12865-016-0169-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados